Relipid+ Balm in mild to moderate atopic dermatitis: a new emollient option for children and adults
Official title: AIMSI Trial : Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
Run by University Hospital, Caen · NCT07358000 · Data updated 2026-11-12
This study tests whether Baume Relipid+ can be used safely and effectively to help people with mild to moderate atopic dermatitis compare to current emollients.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 86 (estimated) |
| Sponsor | University Hospital, Caen Academic / other |
| Locations | 1 site (Caen, Normandy) |
| Status | Recruiting |
| Started | September 1, 2026 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2027 |
| Registry record updated | September 9, 2026 |
| Trial ID | NCT07358000 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children from 6 months to 70 years old with mild to moderate atopic dermatitis (SCORAD < 40) who can start treatment within 72 hours of assessment and are enrolled in the French national health insurance system.
✕Probably not a fit
Patients with more severe disease (SCORAD ≥ 40 or need for systemic therapy) or those who do not participate or consent may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blind, non-inferiority trial compares Baume Relipid+ with a standard emollient in children and adults with mild to moderate atopic dermatitis. Participants aged 6 months to 70 years with SCORAD less than 40 will be enrolled and randomized to receive the Relipid+ balm within 72 hours of initial assessment. The study is conducted at CHU Caen Normandie under a lead sponsor of the University Hospital Caen, aiming to determine if Relipid+ provides similar clinical benefit while potentially reducing treatment burden and cost. All participants must be affiliated with the French national health insurance system and provide informed consent. Those requiring systemic therapy or who decline participation are excluded.
Why it matters
Potential benefit: If successful, Relipid+ balm could offer a convenient and potentially cost-effective option to improve skin symptoms and quality of life for people with mild to moderate atopic dermatitis.
How similar studies have gone: Previous emollient-focused research has shown variable results; this trial tests a novel active oligo skin–based emollient approach in a non-inferiority design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients aged 6 months to 70 years with mild to moderate atopic dermatitis (SCORAD \< 40) Time to treatment initiation \< 72 hours between initial assessment and balm application Affiliated with the French national health insurance system and French-speaking Written informed consent must be obtained Exclusion Criteria: Patients who decline participation Patients under legal guardianship, curatorship, legal protection, or judicial safeguard Patients with a SCORAD indicating the need for systemic therapy
Where it's running
-
CHU Caen Normandie
Caen, Normandy, France Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults
A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.
-
Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin
This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.
-
ADBest TREAT Registry for adults with atopic dermatitis
A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.
-
How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis
This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.
-
QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis
This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.
-
Tilrekimig for moderate-to-severe eczema in teens and adults
A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.